ISIS 104838 is an inhibitor of TNF-alpha and employs a second generation antisense chemistry, according to developers Isis Pharmaceuticals, of Carlsbad, California, USA.
"This Phase I is the first step toward goal of creating a tablet form of ISIS 104838."Dr Andrew Dorr.
It is hoped that the new drug will eventually be made available in tablet form. In conjunction with OraSense Ltd, Isis hopes to begin human trials of tablets or capsules next year.
High levels of TNF-alpha are found in Crohn's disease and there is already a 500 million US dollar market for inhibitory drugs.
Dr Andrew Dorr, chief medical officer of Isis, said: "We are excited about the opportunity to create a more convenient and safer medicine that inhibits TNF-alpha for patients with rheumatoid arthritis and Crohn's disease.
"Inhibition of TNF-alpha is known to be effective in the treatment of these inflammatory diseases. We believe antisense inhibition of TNF-alpha is likely to have fewer side effects and offer an attractive alternative to drugs that are currently used to treat these diseases."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com